Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × dabrafenib × Clear all

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT07440290 2026-02-27

DETERMINE

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04452877 2026-01-13

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

Phase 2 Completed

40 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1 Suspended

71 enrolled

DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

209 enrolled

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

No longer available

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT05988697 2023-10-12

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting

36 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02672358 2018-08-10

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Dabrafenib and/or Trametinib Rollover Study

DETERMINE

A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

EROS

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC